Your browser doesn't support javascript.
loading
The impact of periodontitis and periodontal treatment on rheumatoid arthritis outcomes: an exploratory clinical trial.
Silva, Daniela S; De Vries, Charlotte; Rovisco, João; Serra, Sara; Kaminska, Marta; Mydel, Piotr; Lundberg, Karin; Silva, José P; Baptista, Isabel P.
Afiliação
  • Silva DS; Periodontology Institute, Faculty of Medicine, University of Coimbra, Portugal.
  • De Vries C; CIMAGO, Faculty of Medicine, University of Coimbra, Portugal.
  • Rovisco J; Department of Medicine Solna, Division of Rheumatology, Karolinska Institute, Solna, Sweden.
  • Serra S; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
  • Kaminska M; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
  • Mydel P; Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway.
  • Lundberg K; Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway.
  • Silva JP; Department of Microbiology, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
  • Baptista IP; Department of Medicine Solna, Division of Rheumatology, Karolinska Institute, Solna, Sweden.
Article em En | MEDLINE | ID: mdl-39002123
ABSTRACT

OBJECTIVE:

Studies suggest rheumatoid arthritis (RA) patients could benefit from periodontal treatment. However, published data are inconsistent, and there is a need for better-controlled research. Our study aims to address these limitations.

METHODS:

In this exploratory randomised delayed-start study, 22 RA patients with moderate/severe periodontitis were subjected to full-mouth debridement. Periodontal and rheumatological assessments, including measuring anti-cyclic citrullinated peptide 2 (CCP2) IgG levels, were performed at baseline (V1), 2 months (V2) and 6 months (V3) after step 1 and 2 of periodontal therapy. Primary outcome was changes in disease activity score for 28 joints (DAS28) between V2 and V1. Secondary outcomes were changes in other rheumatological or periodontal clinical parameters (V2 or V3-V1).

RESULTS:

RA disease activity was significantly higher in RA patients with severe periodontitis compared to moderate periodontitis at baseline, with significant positive correlations between several rheumatological and periodontal parameters. After periodontal treatment, RA patients with severe, but not moderate, periodontitis demonstrated significant improvements in DAS28 (ΔV2-V1, p = 0.042; ΔV3-V1, p = 0.001) and significant reduction in anti-CCP2 IgG levels at V3 (p = 0.032).

CONCLUSION:

Periodontal treatment is locally effective in patients with RA and impacts RA disease activity and anti-CCP2 antibody levels in patients with severe periodontitis. Hence, our data suggest that periodontal assessment and treatment should be integrated in the management of RA patients within a treat-to-target strategy. CLINICAL TRIAL REGISTRATION www.isrctn.com, ISRCTN 17950307.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article